ReviewFrontiers in pharmacology2014
Molecular basis of HFE-hemochromatosis.
Review in Frontiers in pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- The risk of new-onset cancer associated with HFE C282Y and H63D mutations: evidence from 87,028 participants.Journal of cellular and molecular medicine · 2016Pooled it
- Hepatic control of immunometabolism: implications for the pathogenesis, diagnosis and treatment of rheumatic diseases.Nature reviews. Rheumatology · 2026Review
- The influences of genetic polymorphisms in three candidate genes on the athletic performance of Korean athletes.Genes & genomics · 2025Article
- Article
- Iron Homeostasis and Energy Metabolism in Obesity.Clinical nutrition research · 2022Review
- Iron at the Interface of Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Cytokine and Gene Expression Profiling in Patients with HFE-Associated Hereditary Hemochromatosis according to Genetic Profile.Acta haematologica · 2021Article
- Conservation of sequence motifs suggests that the nonclassical MHC class I lineages CD1/PROCR and UT were established before the emergence of tetrapod species.Immunogenetics · 2018Article
- Low hepcidin in liver fibrosis and cirrhosis; a tale of progressive disorder and a case for a new biochemical marker.Molecular medicine (Cambridge, Mass.) · 2018Review
- Excess iron: considerations related to development and early growth.The American journal of clinical nutrition · 2017Review
- Bone morphogenetic protein-binding endothelial regulator of liver sinusoidal endothelial cells induces iron overload in a fatty liver mouse model.Journal of gastroenterology · 2017Article
- Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients.Clinical journal of the American Society of Nephrology : CJASN · 2016Review
- Haplotype analysis of the HFE gene among populations of Northern Eurasia, in patients with metabolic disorders or stomach cancer, and in long-lived people.BMC genetics · 2016Article
- Iron Homeostasis in Health and Disease.International journal of molecular sciences · 2016Review
- Human Hemochromatosis Protein (HFE) Immunoperoxidase Stain Highlights Choriocarcinoma within Mixed Germ Cell Tumors.Disease markers · 2016Article
- Buried Treasure: Evolutionary Perspectives on Microbial Iron Piracy.Trends in genetics : TIG · 2015Review
- Bacterial iron-sulfur cluster sensors in mammalian pathogens.Metallomics : integrated biometal science · 2015Review
- Hfe and Hjv exhibit overlapping functions for iron signaling to hepcidin.Journal of molecular medicine (Berlin, Germany) · 2015Article
- Blood and iron.Journal of molecular medicine (Berlin, Germany) · 2015Article
- The importance of iron in pathophysiologic conditions.Frontiers in pharmacology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron-overload disorders owing to genetic misregulation of iron acquisition are referred to as hereditary hemochromatosis (HH). The most prevalent genetic iron overload disorder in Caucasians is caused by mutations in the HFE gene, an atypical MHC class I molecule. Recent studies classified HFE/Hfe-HH as a liver disease with the primarily failure in the production of the liver iron hormone hepcidin in hepatocytes. Inadequate hepcidin expression signals for excessive iron absorption from the diet and iron deposition in tissues causing multiple organ damage and failure. This review focuses on the molecular actions of the HFE/Hfe and hepcidin in maintaining systemic iron homeostasis and approaches undertaken so far to combat iron overload in HFE/Hfe-HH. In the light of the recent investigations, novel roles of extra-hepatocytic Hfe are discussed raising a question to the relevance of the multipurpose functions of Hfe for the understanding of HH-associated pathologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.